TLDR
- Humacyte stock climbs as Symvess sales rise despite wider Q1 loss
- HUMA gains 19% after Q1 update, cost cuts, and trial progress
- Symvess commercial sales improve as Humacyte reports wider loss
- Humacyte cuts 25% of staff while backing Symvess expansion plan
- June dialysis data becomes key milestone after Humacyte Q1 report
Humacyte (HUMA) stock traded at $1.0874, up 19.49%, after the company reported stronger Symvess sales and a wider quarterly loss. The update showed commercial progress, but it also highlighted higher costs and a restructuring plan. Humacyte now aims to sharpen spending while pushing key clinical and commercial milestones.
Symvess Sales Grow as Humacyte Expands Commercial Push
Humacyte reported $0.5 million in Symvess commercial sales during the first quarter of 2026. The company sold 29 units, compared with five units in the same quarter of 2025. Therefore, the product showed early uptake after its U.S. approval for extremity vascular trauma.
Symvess remains central to Humacyte’s commercial strategy because it targets urgent vascular repair cases. The product serves adults who need revascularization when vein graft use remains unsuitable. However, Humacyte said faster sales growth remains necessary because of the product’s potential.
The company also added senior commercial and surgical leaders to support wider adoption. James Mercadante joined as Chief Commercial Officer, while Dr. Todd Rasmussen became Chief Surgical Officer. Moreover, both appointments strengthen Humacyte’s sales, education, and surgical support plans.
Q1 Loss Widens as Costs and Lower Non-Cash Income Weigh
Humacyte reported a first-quarter net loss of $17.6 million for 2026. That result compared with net income of $39.1 million in the first quarter of 2025. The change mainly came from lower non-cash income tied to earnout liability remeasurement.
Research and development expenses rose to $19.5 million from $15.4 million a year earlier. Humacyte linked the increase to material costs for CTEV work and process improvement efforts. These efforts aim to support future manufacturing efficiency and lower cost of goods sold.
Cost of goods sold reached $2.0 million, compared with $0.1 million last year. The figure included costs linked to sold units, an inventory reserve, and unused production capacity. General and administrative expenses stayed nearly flat at $7.9 million.
Cost Cuts and Trial Milestones Shape 2026 Outlook
Humacyte reduced expected spending by $14.3 million for the rest of 2026. The company also cut about 45 positions through layoffs and deferred hiring. As a result, total headcount dropped by about 25%.
The company said the restructuring keeps resources focused on key business goals. These include the Symvess launch, hemodialysis development, and the planned CTEV human study. Additionally, Humacyte expects about $0.8 million in severance and employee termination charges.
Humacyte ended March 31, 2026, with $48.9 million in cash, cash equivalents, and restricted cash. The company used $2.0 million in net cash during the quarter. However, share sales during 2026 generated $23.3 million in net proceeds.
Dialysis Data and International Plans Add New Catalysts
Humacyte plans to present top-line interim dialysis trial results on June 11, 2026. The Phase 3 V012 trial evaluates ATEV for hemodialysis access in female patients. It compares ATEV performance with AV fistulas after one year of follow-up.
The company enrolled 120 patients, while the interim analysis covers the first 80 eligible patients. Subject to results, Humacyte plans a supplemental BLA filing in the second half of 2026. That filing would seek a hemodialysis indication for ATEV.
Humacyte also advanced international and defense-related commercial efforts during the quarter. Israel accepted its Symvess marketing application for review. Additionally, Saudi Arabia delivered a $1.475 million minimum purchase commitment for clinical evaluation and outreach.
Background and Market Context
Humacyte develops bioengineered human tissues for vascular and other medical applications. The FDA approved its ATEV product for extremity vascular trauma in December 2024. Symvess carries a boxed warning for graft failure, including rupture or anastomotic failure.
The company’s broader pipeline includes hemodialysis access, peripheral artery disease, coronary bypass grafts, and other tissue applications. Its CTEV program also moved toward a first human study in coronary artery bypass surgery. Humacyte submitted an IND application and completed a large-scale manufacturing lot.
The latest update gives HUMA stock a clear near-term storyline. Symvess sales improved, but the wider loss and inventory charges showed pressure inside the business. June dialysis data and stronger commercial execution now carry greater weight for Humacyte’s 2026 path.
Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
